Addiction Treatment Options: Inpatient, Outpatient, and MAT Compared
Over 40 million Americans have a substance use disorder. Compare inpatient, outpatient, medication-assisted treatment, and 12-step programs with outcome data.
40 Million Americans Have a Substance Use Disorder — Most Get No Treatment
The 2022 National Survey on Drug Use and Health estimated that 48.7 million Americans aged 12 and older had a substance use disorder (SUD) in the previous year. Of those, only about 22% — roughly 10.7 million people — received any treatment. The treatment gap is driven by cost, stigma, lack of insurance coverage, and insufficient provider capacity, particularly for evidence-based medication-assisted treatment. Understanding what treatment options exist, how they differ in effectiveness, and how costs are structured is essential for individuals and families navigating this public health crisis.
The Continuum of Care
Addiction treatment is not a single intervention but a continuum. The American Society of Addiction Medicine (ASAM) developed a widely used set of placement criteria that matches patients to five levels of care based on assessment across six dimensions: acute intoxication and withdrawal potential, biomedical conditions, emotional and cognitive conditions, treatment readiness, relapse potential, and recovery environment.
- Level 0.5 — Early Intervention: Education and brief counseling for at-risk individuals not yet meeting SUD criteria
- Level 1 — Outpatient: Less than 9 hours per week; standard office-based counseling and MAT
- Level 2.1 — Intensive Outpatient (IOP): 9–19 hours per week; structured programming while patient lives at home
- Level 2.5 — Partial Hospitalization (PHP): 20+ hours per week; near-daily programming without overnight stay
- Level 3 — Residential: 24-hour structured environment; ranges from medically managed detox (3.7) to clinically managed low-intensity (3.1)
- Level 4 — Medically Managed Intensive Inpatient: Hospital-based care for severe withdrawal or co-occurring medical conditions
Medication-Assisted Treatment (MAT)
MAT combines FDA-approved medications with counseling and behavioral therapies. It is the most evidence-supported approach for opioid use disorder (OUD) and alcohol use disorder (AUD). The Substance Abuse and Mental Health Services Administration (SAMHSA) recognizes MAT as the gold standard for OUD, yet fewer than 20% of people with OUD receive it.
| Medication | Indication | Mechanism | Setting |
|---|---|---|---|
| Methadone | Opioid use disorder | Full opioid agonist; reduces cravings and withdrawal | OTP clinic only; daily dosing |
| Buprenorphine (Suboxone) | Opioid use disorder | Partial agonist; ceiling effect reduces overdose risk | Office-based prescribing since 2002 |
| Naltrexone (Vivitrol) | OUD and AUD | Opioid antagonist; blocks euphoric effects | Injectable monthly; no diversion risk |
| Naloxone (Narcan) | Opioid overdose reversal | Opioid antagonist; rapid reversal of overdose | Naloxone available OTC since 2023 |
| Acamprosate | Alcohol use disorder | Reduces post-acute withdrawal symptoms | Oral; office-based |
| Disulfiram (Antabuse) | Alcohol use disorder | Causes aversive reaction to alcohol consumption | Requires motivation; adherence challenging |
Inpatient vs. Outpatient: Comparing Outcomes
No high-quality randomized trial has established that inpatient treatment produces superior long-term outcomes to outpatient treatment across all patients. Outcome differences are largely explained by patient selection — those with more severe addiction, co-occurring psychiatric disorders, unstable housing, or poor social support are more likely to be placed in inpatient settings and also more likely to relapse regardless of treatment intensity.
Research does support residential treatment for patients who have failed multiple outpatient attempts, those with co-occurring serious mental illness, patients in environments with easy drug access, and individuals with active domestic violence situations. A 2017 systematic review in the Journal of Substance Abuse Treatment found no consistent superiority of inpatient over intensive outpatient when baseline severity was controlled.
12-Step Programs and Mutual Aid
Alcoholics Anonymous (AA), founded in 1935 by Bill Wilson and Bob Smith in Akron, Ohio, and its derivative Narcotics Anonymous (NA) are the most widely attended mutual aid programs in the world. AA claims over 2 million members in more than 180 countries. These programs are not treatment in the clinical sense — they charge no fees, employ no professionals, and administer no medications — but function as peer support networks with a 12-step framework centered on admitting powerlessness over addiction and developing spiritual or personal accountability.
Cochrane Review analyses have found that AA attendance is associated with higher rates of continuous abstinence than other approaches, including Motivational Enhancement Therapy, for alcohol use disorder. The SMART Recovery program offers an evidence-based secular alternative for those who prefer a cognitive-behavioral framework without spiritual components.
- AA/NA: Free; spiritual/12-step model; broadest availability; largest evidence base for alcohol
- SMART Recovery: Free; CBT-based; secular; online meetings widely available
- Refuge Recovery: Free; Buddhist-principles framework; mindfulness-based
- LifeRing Secular Recovery: Free; abstinence-based; non-spiritual
Insurance Coverage and Federal Parity Law
The Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA) requires that insurance coverage for mental health and substance use disorders be no more restrictive than coverage for medical and surgical care. The Affordable Care Act designated SUD treatment as an essential health benefit, requiring most individual and small-group plans to cover it.
In practice, coverage enforcement has been inconsistent. Prior authorization requirements, step therapy protocols demanding failed outpatient treatment before inpatient coverage is authorized, and limited in-network provider networks remain significant barriers. The 2021 CAA (Consolidated Appropriations Act) strengthened MHPAEA enforcement requirements for insurers to conduct comparative analyses of their coverage limitations.
This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.
Related Articles
mental health
Acceptance and Commitment Therapy: Psychological Flexibility Over Symptom Removal
ACT is a third-wave behavioral therapy developed by Steven Hayes in 1986 that prioritizes psychological flexibility and valued living over symptom elimination.
9 min read
mental health
Antidepressants Compared: SSRIs, SNRIs, TCAs, and MAOIs
A comprehensive comparison of antidepressant classes covering mechanisms, the STAR*D trial findings, switching strategies, sexual dysfunction rates, and ketamine's rapid-onset mechanism.
9 min read
mental health
Bipolar Disorder Explained: Mania, Depression, and Brain Biology
Bipolar disorder affects 40–50 million people worldwide, causing episodes of mania and depression that can devastate lives. Explore its neurobiological basis, the spectrum of types, and how mood stabilizers work.
9 min read
mental health
Eating Disorder Treatment Options: Programs, Costs, and Insurance
Eating disorders have the highest mortality of any psychiatric condition. Learn about treatment levels, costs ranging $500–$2,000 per day, and insurance coverage.
9 min read